EA201991302A1 - Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1 и лекарственными средствами, ингибиторами контрольных точек иммунного ответа - Google Patents

Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1 и лекарственными средствами, ингибиторами контрольных точек иммунного ответа

Info

Publication number
EA201991302A1
EA201991302A1 EA201991302A EA201991302A EA201991302A1 EA 201991302 A1 EA201991302 A1 EA 201991302A1 EA 201991302 A EA201991302 A EA 201991302A EA 201991302 A EA201991302 A EA 201991302A EA 201991302 A1 EA201991302 A1 EA 201991302A1
Authority
EA
Eurasian Patent Office
Prior art keywords
netrin
medicines
interfering
inhibitors
immune response
Prior art date
Application number
EA201991302A
Other languages
English (en)
Other versions
EA039433B1 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991302A1 publication Critical patent/EA201991302A1/ru
Publication of EA039433B1 publication Critical patent/EA039433B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение представляет собой комбинацию или комбинированное применение (i) соединения, способного нарушать или препятствовать взаимодействию нетрин-1/рецепторы нетрина-1 или опосредованной нетрином-1 димеризации рецептора, также называемого в настоящем документе нейтрализующим агентом NTN1, соединения, которое может представлять собой антитело, связывающееся с нетрином-1, или антитело против нетрина-1, и (ii) ингибитора контрольной точки иммунного ответа в лечении рака. Композиция может включать антитело против нетрина-1 и ингибитор контрольной точки иммунного ответа для применения в качестве противоракового лекарственного средства с одновременным, раздельным или последовательным введением антитела против нетрина-1 и ингибитора контрольной точки иммунного ответа пациенту.
EA201991302A 2017-01-05 2018-01-05 Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа EA039433B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305014 2017-01-05
PCT/EP2018/050289 WO2018127570A1 (en) 2017-01-05 2018-01-05 Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Publications (2)

Publication Number Publication Date
EA201991302A1 true EA201991302A1 (ru) 2019-11-29
EA039433B1 EA039433B1 (ru) 2022-01-27

Family

ID=57838304

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991302A EA039433B1 (ru) 2017-01-05 2018-01-05 Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа

Country Status (10)

Country Link
US (1) US20190315852A1 (ru)
EP (1) EP3565837B1 (ru)
JP (2) JP7211952B2 (ru)
KR (1) KR102679324B1 (ru)
CN (1) CN110291105B (ru)
AU (1) AU2018205730B2 (ru)
CA (1) CA3048347A1 (ru)
EA (1) EA039433B1 (ru)
IL (1) IL267775A (ru)
WO (1) WO2018127570A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102679324B1 (ko) * 2017-01-05 2024-06-28 네트리 파르마 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
US20240342322A1 (en) * 2021-07-27 2024-10-17 Netris Pharma Netrin-1 detection, companion test and therapy based on radiations
AU2023242470A1 (en) * 2022-03-29 2024-10-10 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
SG172645A1 (en) 2006-02-28 2011-07-28 Centre Nat Rech Scient Screening for anti-cancer compounds using netrin-1 activity
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
BR112013004358A2 (pt) 2010-08-26 2017-06-27 Center Leon Berard Centre Regional De Lutte Contre Le Cancer proteína de fusão-dcc, molécula de ácido nucleico, vetor, célula hospedeira, método para produzir a proteína de fusão-dcc, proteína de fusão-dcc, composição farmacêutica, uso e método de tratamento do câncer em um sujeito pela administração da proteína de fusão-dcc.
CN103608040B (zh) 2011-04-20 2017-03-01 米迪缪尼有限公司 结合b7‑h1和pd‑1的抗体和其他分子
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN106913870A (zh) * 2014-06-27 2017-07-04 中国科学院生物物理研究所 用于阻断Netrin‑1与CD146之间的相互作用的试剂及其肿瘤治疗用途
NZ738406A (en) * 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
KR102679324B1 (ko) * 2017-01-05 2024-06-28 네트리 파르마 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료

Also Published As

Publication number Publication date
IL267775A (en) 2019-09-26
AU2018205730A1 (en) 2019-07-11
EP3565837B1 (en) 2024-04-10
US20190315852A1 (en) 2019-10-17
CN110291105A (zh) 2019-09-27
AU2018205730B2 (en) 2024-05-30
KR102679324B1 (ko) 2024-06-28
JP7211952B2 (ja) 2023-01-24
EP3565837A1 (en) 2019-11-13
JP2020503359A (ja) 2020-01-30
WO2018127570A1 (en) 2018-07-12
JP2022176250A (ja) 2022-11-25
CN110291105B (zh) 2024-03-01
KR20190101991A (ko) 2019-09-02
CA3048347A1 (en) 2018-07-12
EP3565837C0 (en) 2024-04-10
EA039433B1 (ru) 2022-01-27

Similar Documents

Publication Publication Date Title
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2021008053A (es) Metodos para monitorear y terapias para usarse en tratar el cancer.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12017502270A1 (en) Combination therapy for the treatment of cancer
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
BR112017021245A2 (pt) Anticorpo anti-c-met e conjugado anticorpo anti- c-met-fármaco citotóxico e uso farmacêutico do mesmo
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
EA201991207A1 (ru) Новые агонисты tnfr и их применение
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
GB201201314D0 (en) Composition
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
EA202091514A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
EA201792304A1 (ru) Комбинированная терапия для лечения рака
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
PH12016502353A1 (en) Pharmaceutical composition
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam